Sugi Predict

Sugi Predict / Compounds / SCHEMBL1014326

SCHEMBL1014326

SCHEMBL1014326

CCOC(=O)/C(=C\N(C)C)C(=O)C1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 2/20 0.46
▸ NPSR1 Q6W5P4 3/20 0.42
▸ GLO1 Q04760 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MAPT P10636 6/20 0.37
▸ MEN1 O00255 5/20 0.37
▸ KMT2A Q03164 5/20 0.37
▸ GAA P10253 2/20 0.36
▸ RECQL P46063 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ S1PR4 O95977 1/20 0.34
▸ S1PR1 P21453 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ IDE P14735 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31587550 1.00 CYP2C9 (0.46) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL1014327 1.00 CYP2C9 (0.46) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL28228568 0.94 CYP2C9 (0.44) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL30550006 0.94 CYP2C9 (0.44) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL15645751 0.86 MAPT (0.46) CYP2C9ALDH1A1CYP2D6SMN1; SMN2MAPT
SCHEMBL15647563 0.86 MAPT (0.46) CYP2C9ALDH1A1CYP2D6SMN1; SMN2MAPT
SCHEMBL24863517 0.86 CYP2C9 (0.43) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL17056961 0.84 ATM (0.39) CYP2C9NPSR1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3230226 0.82 CYP2C9 (0.58) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL1015828 0.81 MAPT (0.36) MAPTMEN1KMT2AGAARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4707276-A2 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2026-03-11 — — EP disclosed
EP-4499611-B1 MALT1 MODULATORS AND USES THEREOF RAREFIED BIOSCIENCES INC (US) 2026-02-18 — — EP disclosed
US-20250326738-A1 MALT1 Modulators and Uses Thereof RAREFIED BIOSCIENCES, INC. (US) 2025-10-23 — — US disclosed
EP-4499611-A1 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2025-02-05 — — EP disclosed
CN-119032083-A MALT1 modulators and uses thereof 稀有生物科学股份有限公司 2024-11-26 — — CN disclosed
WO-2023192506-A1 MALT1 MODULATORS AND USES THEREOF RARIFIED BIOSCIENCES, INC. (US) 2023-10-05 — — WO disclosed
WO-2023192506-A1 MALT1 MODULATORS AND USES THEREOF RARIFIED BIOSCIENCES, INC. (US) 2023-10-05 — — WO disclosed
WO-2022272133-A2 PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS Stablix, Inc. (US) 2022-12-29 — — WO disclosed
US-10947206-B2 cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-03-16 — — US disclosed
US-8344016-B2 Pyrazole derivatives as 11-beta-HSD1 inhibitors ASTRAZENECA AB (SE) 2013-01-01 — — US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 — — US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 — — US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 — — US disclosed
US-20090221663-A1 PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2009-09-03 — — US disclosed
US-20090221663-A1 PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2009-09-03 — — US disclosed
WO-2008099145-A1 PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2008-08-21 — — WO disclosed
US-20060241151-A1 Pyrid-2-one derivatives and methods of use AMGEN, INC. (US) 2006-10-26 — — US disclosed
EP-1575947-A1 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES Amgen Inc. (US) 2005-09-21 — — EP disclosed
US-20040147561-A1 Pyrid-2-one derivatives and methods of use SYNGENTA CROP PROTECTION AG (CH) 2004-07-29 — — US disclosed
WO-2004060890-A1 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES AMGEN INC. (US) 2004-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 CYP2C9 32/4885NPSR1 713/4885GLO1 3277/4885
US-10947206-B2 cGAS antagonist compounds CGAS, STING1, GLS2 CYP2C9 2855/4885NPSR1 185/4885GLO1 3461/4885
US-20250326738-A1 MALT1 Modulators and Uses Thereof MALT1, SQSTM1, PPP1R10 CYP2C9 4544/4885NPSR1 4749/4885GLO1 2055/4885
US-20040147561-A1 Pyrid-2-one derivatives and methods of use PLPBP, PNPO, PDXK CYP2C9 344/4885NPSR1 3531/4885GLO1 921/4885
US-20060241151-A1 Pyrid-2-one derivatives and methods of use PLPBP, PNPO, PDXK CYP2C9 309/4885NPSR1 3457/4885GLO1 1002/4885
US-20090221663-A1 PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS HSD11B1, HSD3B1, HSD11B2 CYP2C9 58/4885NPSR1 1407/4885GLO1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.